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INTRODUCTION 
Currently, Nasal drug delivery has been recognized as a 
very promising route for delivery of therapeutic 
compounds including biopharmaceuticals. Nasal 
administration is a logical choice for topical nasal 
treatments such as antihistamines and corticosteroids. The 
nasal mucosa has also received attention as a viable means 
of systemic administration of analgesics, sedatives, 
hormones, cardiovascular drugs, and vaccines.  
Conventionally, the nasal route has been used for local 
delivery of drugs for treating nasal allergy, nasal 
congestion, or nasal infections. However systemic delivery  
through the nasal route has recently begun to explore 
possibilit ies for those requiring a rapid onset of action or 
necessitating avoidance of severe proteolysis involved in 
oral administration (e.g., most peptide and protein drugs). 
Successful attempts to deliver corticosteroid hormones 
through the nasal route for systemic absorption have 
triggered further studies in this area.
1-3
  
Researchers have studied the anatomical and physiological 
aspects of the nasal membrane, including its vascular 
nature, as they relate to drug delivery.
4-11
 There are three 
distinct functional regions in the nose- the vestibular, 
respiratory, and olfactory. Among these, the respiratory 
region is the most important for systemic drug delivery.
12
 
The respiratory epithelium consists of basal, mucus-
containing goblet, ciliated columnar and non-ciliated 
columnar cell types.
13
 The cilia move in a wavelike fashion 
to transport particles to the pharynx area for ingestion.
14
 
Additionally, the cells in this region are covered by nearly 
300 microvilli, providing a large surface area for 
absorption. Below the epithelium is the lamina propria. 
This is where b lood vessels, nerves, serous glands, and 
mucus secretary glands may be found. The lamina propria 
also houses a dense network of capillaries, through which  
drug absorption takes place. The nasal passage epithelium 
is covered by a mucus layer that is renewed every 10 to 15 
minutes.
15
 The pH of the mucosal secretions ranges from 
5.5 to 6.5 in adults and 5.0 and 6.7 in children.
16
 The 
mucus layer entraps particles, which are then cleared from 
the nasal cavity by the cilia.
17 
 
Figure 1: Schematic of a sagittal section of human nasal cavity 
showing the   nasal vestibule (A), atrium (B), respiratory region: 
inferior turbinate (C1), middle turbinate (C2) and the superior 
turbinate (C3), the olfactory region (D) and nasopharynx (E)18 
1. Nasal Sprays 
 The following test parameters are recommended for nasal 
spray drug products . Appropriate acceptance criteria and 
validated test procedures should be established for each 
test parameter. 
EVALUATION PARAMETERS : 
(For Nasal Spray dosage form - Inhalation Solutions, 
Suspensions, and S prays)
19-22
 
a. Appearance, Color, and Clarity: 
 The appearance of the content of the container (i.e ., 
formulat ion) and the container closure system (e.g., pump 
components, inside of the container) should conform to  
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their respective descriptions as an indication of the drug 
product integrity. If any color is associated with the 
formulat ion (either present initially or from degradative 
processes occurring during shelf life) then a quantitative 
test with appropriate acceptance criteria should be 
established for the drug product by the manufacturer.  
b. Identi fication: 
 A specific identification test(s) is recommended to verify 
the identity of the drug substance in the drug product. 
Chromatographic retention time alone is not an adequate 
method to ensure the identity of the drug substance in the 
drug product. If the drug substance is a single enantiomer, 
then at least one of the methods should be specific for this 
property. 
c. Drug Content (Assay): 
 The assay of drug substance in the entire container should 
be determined analytically with a stability indicat ing 
procedure. This test provides assurance of consistent 
manufacturing (e.g., formulation, filling, sealing). The 
acceptance criteria ( assay limits as specified in official 
books) should be tight enough to ensure conformance in  
other related attributes (e.g., spray content uniformity). A  
suitable assay procedure should be designed to address any 
degradation of the drug substance, adherence of the drug 
substance to the container and closure components, and the 
potential effect of formulat ion evaporation and/or leakage.  
 d. Impurities and Degradation Products : 
The levels of degradation products and impurities should 
be determined by means of stability indicat ing 
procedure(s). Acceptance criteria should be set for 
individual and total degradation products and impurit ies. 
For identificat ion and qualification thresholds, refer to the 
appropriate guidance. All related impurities appearing at 
levels of 0.1 percent or greater should be specified. 
Specified impurities and degradation products are those, 
either identified or unidentified, that are individually listed 
and limited in the drug product specification. 
 e. Preservative(s) and Stabilizing Excipient(s) Assay: 
 If p reservatives, antioxidants, chelating agents, or other 
stabilizing excip ients (e.g.,  benzalkonium chloride, 
phenylethyl alcohol, edetate) are used in the formulation,  
there should be a specific assay for these components with 
associated acceptance criteria (At a concentration of 0.10 
percent or 1.0 milligram per day). 
f. Pump Delivery: 
 A test to assess pump-to-pump reproducibility in terms of 
drug product performance and to evaluate the metering 
ability of the pump should be performed. The proper 
performance of the pump should be ensured primarily by 
the pump manufacturer, who should assemble the pump 
with parts of precise dimensions. Pump spray weight 
delivery should be verified by the applicant for the drug  
product. In general, pump spray weight delivery  
acceptance criteria should control the weight of the 
individual sprays to within ±15 percent of the target weight 
and their mean weight to within ±10 percent of the target 
weight. 
 
 g. S pray Content Uniformity (SCU): 
The spray discharged from the nosepiece should be 
thoroughly analyzed for the drug substance content of 
multip le sprays from an ind ividual container, among 
containers, and among batches of drug product. This test 
should provide an overall performance evaluation of a 
batch, assessing the formulation, the manufacturing 
process, and the pump. The number of sprays per 
determination should not exceed the number of sprays per 
single dose. A single dose represents  the minimum number 
of sprays per nostril specified in the product labeling. To 
ensure reproducible in vit ro dose collection, the procedure 
should have controls for actuation parameters (e.g., stroke 
length, depression force). The test may be performed with 
units primed following the instructions in the labeling. The 
amount of drug substance delivered from the nosepiece 
should be expressed both as the actual amount and as a 
percent of label claim. This test is designed to demonstrate 
the uniformity of medication per spray (or min imum dose), 
consistent with the label claim, d ischarged from the 
nosepiece, of an appropriate number (n = 10 is 
recommended) of containers from a batch. The primary  
purpose is to ensure SCU within the same container and 
among multiple containers of a batch. The following 
acceptance criteria are recommended: 
 The amount of active ingredient per determination is 
not outside of 80–120 percent of label claim for more 
than 1 of 10 containers, none of the determinations is 
outside of 75–125 percent of the label claim, and the 
mean is not outside of 85–115 percent of label claim. 
 If 2 or 3 of the 10 determinations are outside of 80–
120 percent of the label claim, none is outside of 75–
125 percent of label claim, and the mean is not outside 
of 85–115 percent of label claim, an additional 20 
container should be sampled (second tier). For the 
second tier of testing of a batch, the amount of active 
ingredient per determination is not outside of 80–120 
percent of the label claim for more than 3 of all 30 
determinations, none of the 30 determinations is 
outside of 75–125 percent of label claim, and the 
mean is within 85–115 percent of label claim.  
 h. S pray Content Uniformity (SCU) through container 
life: 
The purpose of this test is to assess whether the product 
delivers the labeled number of fu ll medicat ion sprays 
meet ing SCU acceptance criteria throughout the life of the 
nasal spray unit. The test involves determining the SCU 
from the beginning of unit life and at the label claim 
number of sprays per container for an appropriate number 
of containers (n = 5 is recommended). The following 
acceptance criteria are recommended. 
 The amount of active ingredient per determination is 
not outside of 80–120 percent of label claim for more 
than 1 of 10 determinations from five containers, none 
of the determinations is outside of 75–125 percent of 
the label claim, and the means for each of the 
beginning and end determinations  are not outside of 
85–115 percent of label claim. 
 If 2 or 3 of the 10 determinations are outside of 80–
120 percent of the label claim, none is outside of 75–
125 percent of label claim, and the means for each of 
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the beginning and end determinations are not outside 
of 85–115 percent of label claim, an additional 10 
containers are sampled at the beginning of unit life 
and at the label claim number of sprays (second tier). 
For the second tier of testing of a batch, the amount of 
active ingredient per determination is not outside of 
80–120 percent of the label claim for more than 3 of 
all 30 determinations, none of the 30 determinations is 
outside of 75–125 percent of label claim, and the 
means for each of the beginning and end 
determinations are not outside of 85–115 percent of 
label claim. 
i. Spray Pattern and Plume Geometry: 
Characterizat ions of spray pattern and plume geometry are  
important for evaluating the performances of the pump 
and nozzle. Various factors can affect the spray pattern 
and plume geometry, including the size and shape of the 
nozzle, the design of the pump, the size of the metering 
chamber, and the characteristics of the formulation. Spray  
pattern testing should be performed on a routine basis as a 
quality control for release of the drug product. However, 
the characterization of plume geometry should typically  
be established during the characterization of the product 
and is not necessarily tested routinely thereafter. The 
proposed test procedure for spray pattern, including 
analytical sampling plans, should be provided in detail to 
allow duplicat ion by agency laboratories. For example, in  
the evaluation of the spray pattern, the spray distance 
between the  nosepiece and the collection surface, number 
of sprays per spray pattern, position and orientation of the 
collection surface relat ive to the nosepiece, and 
visualizat ion procedure should be specified. The 
acceptance criteria for spray pattern should include the 
shape (e.g., ellipsoid of uniform density) as well as the 
size of the pattern (e.g., no axis is greater than x 
millimeters and the ratio of the longest to the shortest axes 
should lie  in a specified range, for example, 1.00–1.20). 
The spray pattern should be determined, preferab ly by a 
procedure specific for the drug substance, at different 
distances (e.g., two) from the nosepiece to provide greater 
discriminatory capability to the test. Variability in the test 
can be reduced by the development of a sensitive 
detection procedure and by providing procedure 502 
specific training to the analyst. 
 j. Droplet Size Distribution: 
 For both suspension and solution nasal sprays, the 
specifications should include an appropriate control for the 
droplet size d istribution (e.g., 3 to 4 cut-off values) of the 
delivered plume subsequent to spraying under specified 
experimental and instrumental conditions. Appropriate and 
validated dynamic plume droplet size analytical 
procedures should be described in sufficient detail to allow 
accurate assessment by Agency laboratories (e.g., 
apparatus and accessories, software version and calculation 
algorithms, sample placement, laser trigger condition,  
measurement range, beam width).  
 k. Particle Size Distribution (Suspensions): 
 For suspension nasal sprays, the specification should 
include controls for the particle size distribution of the 
drug substance particles in the formulation. Th is 
quantitative procedure should be appropriately validated in 
terms of its sensitivity and ability to detect shifts that may 
occur in the distribution. The acceptance criteria should 
control the complete distribution and should reflect the 
data obtained for the submitted batches (e.g., clinical, 
preclin ical, biobatch, primary stability, production). 
l. Microscopic Evaluation (Sus pensions): 
This test, which involves a qualitative and semi 
quantitative microscopic examination of the suspension 
formulat ions, is complementary to particle size d istribution 
testing for both release and stability purposes. For 
example, the examination provides information on the 
presence of large particles and changes in morphology of 
the drug substance particles, extent of agglomerates, and 
crystal growth. Additionally, where changes in the solid 
state of the drug substance can affect the bioavailability, 
performance, stability, or other properties of the drug 
product, microscopic evaluation or other appropriate 
procedures are recommended to control and monitor 
changes that are observed on stability.  
 
 m. Foreign Particulates: 
For both solution and suspension nasal sprays, there should 
be validated tests and associated acceptance criteria for 
foreign particulates. Foreign particulates may orig inate 
during manufacturing, from formulat ion components, and, 
in particular, from the container and closure components. 
Levels of foreign particulates in the drug product may 
increase with time, temperature, and stress. 
 n. Microbial Limits: 
 The microbial quality should be controlled by appropriate 
tests and acceptance criteria for total aerobic count, total 
yeast and mold count, and freedom from designated 
indicator pathogens. Acceptance criteria should be 
reflective of the data for the submitted batches (e.g., 
clin ical, preclin ical, biobatch, primary stability, 
production), but at a min imum should meet the 
recommended microbial limits  acceptance criteria in USP 
<1111>, Microbio logical Attributes for Non-sterile  
Pharmacopeial Articles. Furthermore, appropriate testing 
should show that the drug product does not support the 
growth of microorganis ms and that microbio logical quality 
is maintained throughout the expiration dating period. For 
a description of this test, refer to the procedure in USP 
<61>. 
o. Preservative Effectiveness: 
For nasal sprays that contain a preservative(s), stability 
testing should include microbial challenge studies 
performed on the first three production batches of drug 
product.  
p. Net Content and Weight Loss (Stability): 
 Nasal spray drug products should include acceptance 
criteria for net content and weight loss on stability. Since 
storage orientation plays a key role in any weight loss, the 
drug product should be stored in upright and inverted or 
upright and horizontal positions to assess this 
characteristic. 
The total net content of all fo rmulat ion components in the 
entire container should  be determined. The net content of 
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each of 10 test containers should be in accordance with the 
release specification. For a description of this test, refer to 
the procedure in USP Chapter <755> Min imum Fill.  
 q. Leachables (Stability): 
The drug product should be evaluated for compounds that 
leach from elastomeric or plastic components of the 
container closure system, such as nitrosamines, monomers, 
plasticizers, accelerators, antioxidants, and vulcanizing 
agents. The development of appropriate analytical 
procedures to identify, monitor, and quantify the leached 
components in the drug product should be done during 
investigational studies. These validated procedures can, in 
turn, be used for testing of the drug product throughout the 
expirat ion dating period. Appropriate acceptance criteria 
for the levels of leached compounds in the formulat ion 
should be established.  
r. pH: 
For both solution and suspension nasal sprays, the apparent 
pH of the formulation should be tested and an appropriate 
acceptance criterion established. Lysozyme is found in  
nasal secretions, which is responsible for destroying 
certain bacteria at acidic pH. Under alkaline conditions, 
lysozyme is inactivated and the nasal tissue is susceptible 
to microbial in fection. It is therefore advisable to keep the 
formulat ion at a pH of 4.5 to 6.5 keeping in mind the 
physicochemical properties of the drug as drugs are 
absorbed in the un-ionized form
23
 
 s. Osmolality: 
The osmolality of the fo rmulat ion should be tested and 
controlled with an appropriate procedure and acceptance 
developed by manufacturer. 
CONCLUS ION: 
The quality control of Nasal Spray is critical area where 
high standards are to be maintained therefore evaluation of 
different parameters discussed in this review shows strict 
pharmacovigilance as far as such type of dosage forms are 
concerned. Impurities and Degradation Products, 
Preservative(s) and Stabilizing Excipient(s) Assay, Pump 
Delivery, Spray content uniformity, Spray Content 
Uniformity (SCU) through Container Life, Spray Pattern 
and Plume Geometry, Droplet Size Distribution, Particle 
size distribution (suspension), Microscopic Evaluation 
(Suspensions), Foreign Particulates,  Microbial limit,  
Preservative Effectiveness, Net Content and Weight Loss 
(Stability), Leachables (Stability), PH, Osmolality. The 
acceptance criteria for these parameters have been 
recognized by officials books all over the world.  The 
attempts to deliver corticosteroid hormones through the 
nasal route for systemic absorption have triggered further 
studies and strict control over the delivered dosage. 
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